CURRENT
ISSUE
1561

The FDA has approved baloxavir marboxil (Xofluza – Shionogi/Genentech), the first polymerase acidic (PA) endonuclease inhibitor, for single-dose, oral treatment of acute uncomplicated influenza in patients ≥12 years old. Baloxavir is the first drug with a new mechanism of action to be approved for treatment of influenza in almost 20 years.

STANDARD TREATMENT — Neuraminidase inhibitors, which are active against both influenza A and B viruses, have been the drugs of choice for treatment and prophylaxis of influenza for many years. They are most effective when started within 48 hours after...  Continue reading

More from Issue 1561
Previous Issue: 1560      November 19, 2018
Coming Soon
Drugs for Insomnia
Drugs for Cough
Aripiprazole with Digital Ingestion Tracking (Abilify MyCite)
Antiviral Drugs for Seasonal Influenza 2018-2019
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
FROM
ISSUE
1561

The FDA has approved a new 2.5-mg formulation of the direct factor Xa inhibitor rivaroxaban (Xarelto – Janssen) for use in combination with low-dose aspirin to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). Rivaroxaban is the first direct oral anticoagulant to be approved for this indication. It was approved earlier for prevention and treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.1,2

SECONDARY PREVENTION — Most expert clinicians recommend aspirin 81-162 mg/day indefinitely for patients with atherosclerotic vascular disease (excluding those ... Continue reading